These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29643987)

  • 21. Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival.
    Tang W; Zhou M; Dorsey TH; Prieto DA; Wang XW; Ruppin E; Veenstra TD; Ambs S
    Genome Med; 2018 Dec; 10(1):94. PubMed ID: 30501643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
    Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re-definition of claudin-low as a breast cancer phenotype.
    Fougner C; Bergholtz H; Norum JH; Sørlie T
    Nat Commun; 2020 Apr; 11(1):1787. PubMed ID: 32286297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer.
    Yang G; Zuo C; Lin Y; Zhou X; Wen P; Zhang C; Xiao H; Jiang M; Fujita M; Gao XD; Fu F
    Front Oncol; 2023; 13():1127446. PubMed ID: 37064116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.
    Kumar S; Bhattacharyya S; Das A; Singh G; Bal A
    Breast Dis; 2022; 41(1):241-247. PubMed ID: 35431224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Illuminating function of the understudied druggable kinome.
    Gomez SM; Axtman AD; Willson TM; Major MB; Townsend RR; Sorger PK; Johnson GL
    Drug Discov Today; 2024 Mar; 29(3):103881. PubMed ID: 38218213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.
    Grit JL; Pridgeon MG; Essenburg CJ; Wolfrum E; Madaj ZB; Turner L; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32245042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Label-free proteomic analysis of breast cancer molecular subtypes.
    Panis C; Pizzatti L; Herrera AC; Corrêa S; Binato R; Abdelhay E
    J Proteome Res; 2014 Nov; 13(11):4752-72. PubMed ID: 25221861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling.
    Zhang L; Holmes IP; Hochgräfe F; Walker SR; Ali NA; Humphrey ES; Wu J; de Silva M; Kersten WJ; Connor T; Falk H; Allan L; Street IP; Bentley JD; Pilling PA; Monahan BJ; Peat TS; Daly RJ
    J Proteome Res; 2013 Jul; 12(7):3104-16. PubMed ID: 23692254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer.
    Essegian D; Khurana R; Stathias V; Schürer SC
    Cell Rep Med; 2020 Oct; 1(7):100128. PubMed ID: 33205077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.
    Fink LS; Beatty A; Devarajan K; Peri S; Peterson JR
    Mol Cancer Ther; 2015 Jan; 14(1):298-306. PubMed ID: 25344583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification.
    Yanovich G; Agmon H; Harel M; Sonnenblick A; Peretz T; Geiger T
    Cancer Res; 2018 Oct; 78(20):6001-6010. PubMed ID: 30154156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
    Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
    Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.
    Logullo AF; Pasini FS; Nonogaki S; Rocha RM; Soares FA; Brentani MM
    Mol Clin Oncol; 2018 Oct; 9(4):377-388. PubMed ID: 30214726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
    Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
    Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. STAT3 and GR Cooperate to Drive Gene Expression and Growth of Basal-Like Triple-Negative Breast Cancer.
    Conway ME; McDaniel JM; Graham JM; Guillen KP; Oliver PG; Parker SL; Yue P; Turkson J; Buchsbaum DJ; Welm BE; Myers RM; Varley KE
    Cancer Res; 2020 Oct; 80(20):4355-4370. PubMed ID: 32816914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.